NCT04365699View on ClinicalTrials.gov

Cardiovascular Effects of COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

April 8, 2020

Primary Completion Date

January 31, 2021

Study Completion Date

January 31, 2021

Conditions
COVID-19
Interventions
DRUG

AT-001

Investigational novel Aldose Reductase Inhibitor (ARI) Product: AT-001 500mg capsule for oral administration Dosage: 1,500mg (3X500mg capsules) twice daily Mode of Administration: Oral Up to 14 days per discretion of the investigators and treatment team

Trial Locations (1)

10016

NYU Langone Health, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT04365699 - Cardiovascular Effects of COVID-19 | Biotech Hunter | Biotech Hunter